<DOC>
	<DOCNO>NCT00720798</DOCNO>
	<brief_summary>This single-arm study evaluate long-term efficacy safety tocilizumab participant complete treatment tocilizumab core study ( NCT00106522 [ Roche protocol WA18062 ] , NCT00106574 [ Roche protocol WA18063 ] , NCT00109408 [ Roche protocol WA17824 ] ) adult rheumatoid arthritis . Participants receive tocilizumab alone combination standard anti-rheumatic treatment .</brief_summary>
	<brief_title>An Extension Study Tocilizumab ( Myeloma Receptor Antibody MRA ) Patients Completing Treatment Tocilizumab Core Studies</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Patients complete participation 1 core study adult rheumatoid arthritis . Treatment investigational agent since last administration study drug core study . Treatment iv gamma globulin , plasmapheresis , prosorba column since last administration study drug core study . Treatment antiTNF antiIL1 agent , Tcell costimulation modulator , biologic since last administration study drug core study . Immunization live/attenuated vaccine since last administration study drug core study . Previous treatment celldepleting therapy , include investigational agent . Parenteral , intramuscular , intraarticular corticosteroid within 6 week prior baseline study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>